Abstract:e13606 Background: The advent of next-generation sequencing has greatly facilitated physicians in recommending tailored treatments for cancer patients. Despite these advancements, the dependence on the primary tumor site remains crucial for accurate diagnoses, posing a substantial obstacle in cases of carcinomas of unknown primary (CUPs) and hindering optimal patient care. To address this challenge, we propose the implementation of a machine learning model capable of identifying the tissue of origin (TOO) across 16 cancer types. Current standards gravitate to the use of tumor tissue for identifying primary tumor site. Leveraging the advantages of cell-free DNA (cfDNA), our approach provides a non-invasive and highly sensitive alternative to traditional biopsy or radiography methods. Methods: Cell-free DNA was extracted from patients diagnosed with carcinoma of known origin. The model underwent training using a dataset comprising 2,793 cfDNA samples, while the validation set consisted of 1,863 samples. The training and validation cohorts exhibited comparable demographics in terms of sex, age, and cancer types. Employing low-coverage whole genome sequencing (WGS), samples were analyzed to capture cfDNA features, including DNA fragment size distribution, copy number variation, nucleosome coverage pattern, mutational signature, and hotspot regions associated with cancer-related mutations. The final prediction model's accuracy was evaluated based on top 1 and top 2 predictions in accordance with the true tumor site of origin. Results: Overall accuracy of TOO predictions in the training cohort is 80.20% (2240/2793) for top 1 site and 90.26% (2521/2793) for top 2 sites. Overall accuracy of TOO predictions in the validation cohort is 81.80% (1524/1863) for top 1 site and 90.07% (1678/1863) for top 2 sites. Accuracy of tumor site prediction in the validation cohort is highest for lung cancer (Top 1 = 95.9%; Top 2 = 98.0%) tumor sites and lowest for biliary system and kidney tumor types (Top 1 = 54.3% & 57.4%; Top 2 = 71.6% & 63.2%). In the clinical setting, TOO estimation of 12/16 patients with CUP were identified to be in concordance with majority pathological consensus. Of note, two patients with CUP were diagnosed as lung cancer patients through TOO estimation. Molecular biomarkers of lung adenocarcinoma were also identified through targeted sequencing which corroborated the diagnosis, and chemoradiotherapy was recommended to the patient. Conclusions: We developed an accurate predictor of TOO by leveraging machine learning algorithm and incorporating cfDNA mutational, fragmentomic, and epigenetic features. Our results demonstrate high concordance between model-predicted and actual tumor sites across all examined cancer types. This model shows promise in offering valuable insights for the identification of cancers with an unknown primary origin using non-invasive cell free DNA samples.

A Naive Bayes Algorithm for Tissue Origin Diagnosis (Tod-Bayes) of Synchronous Multifocal Tumors in the Hepatobiliary and Pancreatic System

A CNV Computational Model for Clonal Origin Analysis of Synchronous Multifocal Hepatobiliary and Pancreatic Tumors.

TOD-CUP: a Gene Expression Rank-Based Majority Vote Algorithm for Tissue Origin Diagnosis of Cancers of Unknown Primary

Identifying The Clonal Origin Of Synchronous Multifocal Tumors In The Hepatobiliary And Pancreatic System Using Multi-Omic Platforms

Validation of a 90-Gene Assay for Tissue Origin Diagnosis of Brain Metastases.

A Neural Network Framework for Predicting the Tissue-of-Origin of 15 Common Cancer Types Based on RNA-Seq Data.

Identification of Molecular Subtypes for Integrated Multi-Omics Analysis for Use in Guiding Precision Medicine in Hepatocellular Carcinoma.

An ultrasensitive approach for cancer screening and tissue of origin prediction based on targeted methylation sequencing of cell-free DNA.

TOOme: A Novel Computational Framework to Infer Cancer Tissue-of-Origin by Integrating Both Gene Mutation and Expression

Utility of liquid biopsy for predicting cancer type and informing treatment of carcinoma with unknown primary.

A machine learning framework to trace tumor tissue-of-origin of 13 types of cancer based on DNA somatic mutation.

TOTEM: a multi-cancer detection and localization approach using circulating tumor DNA methylation markers

Tumor origin identification through machine learning and gene expression profiling.

Predicting Cancer Tissue-of-Origin by a Machine Learning Method Using DNA Somatic Mutation Data.

A cross-cohort computational framework to trace tumor tissue-of-origin based on RNA sequencing

Multiclass cancer diagnosis using tumor gene expression signatures

Multi-cancer detection and tissue of origin determination based on 5-hydroxymethylcytosine biomarkers in circulating cell-free DNA.

Parallel Analyses of Somatic Mutations in Plasma Circulating Tumor DNA (ctDNA) and Matched Tumor Tissues in Early-Stage Breast Cancer

Pan-cancer Transcriptome Analysis Reveals a Gene Expression Signature for the Identification of Tumor Tissue Origin.

92-Gene Molecular Profiling in Identification of Cancer Origin: a Retrospective Study in Chinese Population and Performance Within Different Subgroups.

Molecular profiling of Chinese patients with advanced hepatocellular carcinoma using circulating tumor DNA.